Börsipäev 9. detsember
Kommentaari jätmiseks loo konto või logi sisse
-
Peale Hiina, alustasid suuremad aktsiaturud nädalat negatiivsel toonil. S&P 500 indeks langes 0,7%, kui turgu vedasid allapoole energia ja toorainete sektor. Eilse 3,9%-lise langusega andsid energeetikaettevõtted eelmise nädala tõusu tagasi. USA toornafta hind kukkus 5,5%, lõpetades $63,10 peal barrelist, mis märgib madalaimat taset alates 2009. aasta augustist. Hiina väliskaubanduse statistika survestas ka teiste toormete nagu vase ja rauamaagi hindasid. Euroopas lõpetas Stoxx 600 kauplemissessiooni samuti 0,7% miinuses.
Makrokalender jääb täna jällegi suhteliselt hõredaks, kui avaldamisele tulevad Saksamaa ja Prantsusmaa väliskaubanduse statistika, Suurbritannia tööstustoodangu muutus ning USA hulgimüüjate varude muutus.
09.00 Saksamaa väliskaubanduse statistika (oktoober)
09.45 Prantsusmaa väliskaubanduse statistika (oktoober)
11.30 Suurbritannia tööstustoodangu muutus (oktoober)
17.00 Hulgimüüjate varude muutus (oktoober)
Hiina aktsiaturud on tänase volatiilse kauplemissessiooni järel kauplemas 1,7% miinuses, olles vahepeal kaubelnud 2% plusspoolel. Väidetavalt on Hiina kehtestanud karmimad nõuded tagatiseks seatavatele ettevõtete võlakirjadele, mida kasutatakse lühiajaliste laenude saamiseks. Hiina seitsmeaastase võlakirja tulusus kerkis 3,78% pealt 4%-ni.
USA ja Euroopa aktsiaindeksite futuurid on kauplemas 0,3% miinuses. -
Saksamaa väliskaubanduse ülejääk oli oktoobris €20,6 miljardit vs €17,8 miljardit aasta tagasi samal ajal. Saksamaa eksportis kaupu €103,9 miljardi väärtuses (+4,9% yoy) ning importis €81,9 miljardi väärtuses kaupu (+0,9% yoy).
-
Prantsusmaa eksportis oktoobris €36,9 miljardi väärtuses kaupu ning imporditud kaupade väärtus oli €41,5 miljardit. Seega oli riigi väliskaubanduse puudujääk oktoobris €4,6 miljardit. Lisaks avaldati, et riigi oktoobrikuu valitsuse eelarve puudujäägiks kujunes €84,7 miljardit.
-
Väidetavalt plaanib Hiina valitsus langetada riigi 2015. aasta majanduskasvu prognoosi 7% peale varasema 7,5% pealt. Tegemist on esmakordse kärpega viimase kolme aasta jooksul - 2012. aastal langetas Hiina valitsus SKT kasvuprognoosi 7,5% peale varasema 8% pealt.
-
Briti jaemüüja Tesco aktsia kaupleb 11-aasta madalaimal asemel (-10% @ 168,5 penni), kuna ettevõte andis järjekordse kasumihoiatuse. Tesco prognoosib majandusaasta ärikasumiks mitte rohkem kui 1,4 mld naela augustis prognoositud £2,4-2,5 mld asemel. Võrdlusena, konsensus ootas ettevõtte ärikasumiks £2 mld. Tesco kasumit survestab konkurentsisurvest tulenev investeeringute kasv.
Tesco aktsia viimase kolme aasta graafik: -
Gapping down
In reaction to disappointing earnings/guidance: CONN -40.2%, UTIW -6.6%, PLAB -6.3%, AEY -5.9%, HRB -5.6%, PBY -5.1%, GTIM -3.1%, MTL -3%, HDS -2.6%, VZ -1.8% (co expects that Q4 impacts of its promotional offers, together with the strong customer volumes this quarter, will put short-term pressure on its wireless segment EBITDA and EBITDA service margin), ABM -0.9%
M&A news: MRK -2.5% (issues statement regarding CUBICIN patent litigation; reaffirms Cubist (CBST) transaction to proceed as planned - expected to close in first quarter of 2015), CBST -0.8%.
Select financial related names showing weakness: BCS -2.3%, IRE -1.7%, DB -1.5%, HSBC -1.4%, BAC -1.1%, C -1.1%.
Select metals stocks trading lower: AA -2.7%, BHP -2.2%, X -2.0%, RIO -1.9%
Select Chinese names showing early weakness: JRJC -3.8%, LFC -3.4%, BABA -2.4%, JD -1.7%
Other news: ANV -12.9% (announced public offering of common stock and warrants, size not disclosed), NBG -11.2% (Greece mkts down 11% today), GREK -10.5% (Greece ETF, gov called for snap elections), TASR -5.9% (unfavorable commentary on Monday's Mad Money), MANU -5.8% (announced the offering of 3 mln shares of its Class A Ordinary Shares by a selling shareholder), SAVE -5.3% (provided Q4 and 2015 guidance - co noticed some 'dilutive pricing arising from the change in capacity related to the expiration of the Wright Amendment'), TMUS -4.3% (announced proposed public offering of 17,391,305 shares of mandatory convertible preferred stock, with a liquidation preference of $50 per share), PBR -3.5% (still checking), PES -3.5% (expects CapEx to be reduced to $195-215 mln), SHPG -2.8% (still checking), INSY -2.8% (granted orphan drug designation to its Liposome Entrapped Paclitaxel Easy to Use candidate for the treatment of gastric cancer), TSLA -2.5% (most likely down with market weakness, however co officially launches in Australia), SD -2.4% (declared semi-annual preferred stock dividend fo $4.25 per share), BTE -2.3% (announces 2015 budget and change to dividends), TWTR -1.8% (likely down in tandem with market weakness), LHO -1.8% (announced sale of 7.6 mln common shares), ABGB -1.7% (still checking), YHOO -1.7% (likely in sympathy with BABA), AAPL -1.4% (likely down in tandem with market weakness), VALE -1.1% (announced that it entered into an investment agreement with Mitsui & Co), AMZN -1.1% (ChannelAdvisor reported Amazon's (AMZN) November SSS +35.7%)
Analyst comments: SAVE -5.3% (downgraded to Mkt Perform from Outperform at Raymond James), SHPG -2.7% (downgraded to Neutral from Buy at BofA/Merrill), SEIC -2% (downgraded to Mkt Perform from Outperform at Keefe Bruyette), VZ -1.9% (downgraded to Neutral from Outperform at Robert W. Baird), M -1.7% (downgraded to Neutral from Overweight at Atlantic Equities), LPX -1.2% (downgraded to Neutral from Buy at Longbow), GSK -1% (downgraded to Underperform from Neutral at BofA/Merrill).
Gapping up
In reaction to strong earnings/guidance: AZO +3.3%, BURL +3.2%
M&A news: TLM +4.8% (confirms it has been approached by a number of parties, including Repsol (REPYY), with regards to various transactions)
Select mining stocks trading higher: ABX +2.5%, AUY +2.5%, GG +2.4%, PAAS +2%, NEM +1.9%, SLV +1.9%, HMY +1.7%
Select oil/gas related names showing strength: HK +3.2%, SDRL +2.9%, DO +1.1%, GDP +1%, RIG +0.8%
Other news: BLUE +51.2% (announced data demonstrating first four patients with beta-thalassemia major treated with LentiGlobin are transfusion-free), CANF +12% (will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction), MZOR +9.2% (receives purchase orders for three Renaissance systems in Asia), CTP +8.6% (announces withdrawal of public offering), PDCE +5.8% (announced 2015 capital budget of $557 mln and production guidance of 13.8-14.5 mln Boe or ~50% yoy growth), PQ +4.6% (announces significant discovery at its Thunder Bayou Prospect), LLY +3% (Eli Lilly and Incyte (INCY) announced positive top-line results from Phase 3 Trial of Baricitinib in moderate to severe rheumatoid arthritis; met its primary endpoint ), HSP +2.3% (received a favorable ruling in patent case against Cubist/Merck (CBST, MRK)) CTIC +1.3% (presented at ASH)
Analyst comments: LULU +1.9% (upgraded to Outperform from Market Perform at Wells Fargo), FGEN +1.6% (initiated with a Buy at Goldman and initiated with a Outperform at RBC Capital Mkts), AEO +1.3% (upgraded to Outperform at Oppenheimer), LECO +0.7% (upgraded to Buy from Neutral at Longbow)
Allikas: Briefing.com
